相似文献
1
The VEGF family in cancer and antibody-based strategies for their inhibition.
MAbs. 2010 Mar-Apr;2(2):165-75. doi: 10.4161/mabs.2.2.11360.
2
Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):59-71. doi: 10.2174/157489207779561426.
3
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Curr Med Chem. 2006;13(16):1845-57. doi: 10.2174/092986706777585059.
4
Novel small-molecule inhibitors of the vascular endothelial growth factor receptor.
Clin Lung Cancer. 2007 Feb;8 Suppl 2:S74-8. doi: 10.3816/clc.2007.s.005.
5
VEGF inhibitors in cancer therapy.
Curr Pharm Des. 2006;12(3):387-94. doi: 10.2174/138161206775201910.
6
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
Cancer Control. 2007 Jul;14(3):285-94. doi: 10.1177/107327480701400312.
7
Anti-Angiogenics: Current Situation and Future Perspectives.
Oncol Res Treat. 2018;41(4):166-171. doi: 10.1159/000488087. Epub 2018 Mar 23.
8
The role of antiangiogenesis therapy: bevacizumab and beyond.
Clin Transl Oncol. 2009 Jun;11(6):349-55. doi: 10.1007/s12094-009-0368-0.
9
The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Semin Oncol. 2005 Dec;32(6 Suppl 10):S23-9. doi: 10.1053/j.seminoncol.2005.10.005.
10
Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.
Cancer Metastasis Rev. 1999;18(4):473-81. doi: 10.1023/a:1006358220123.
引用本文的文献
1
Design, antiproliferative potency, and in silico studies of novel 5-methylfuran-3-yl)thio)-3-phenylquinazolin-4(3H)-one based derivatives as potential EGFR inhibitors.
Sci Rep. 2025 Jul 31;15(1):27992. doi: 10.1038/s41598-025-12140-1.
2
Cardiac magnetic resonance imaging in the assessment of cardiac injury and toxicity from cancer-related chemotherapy.
Pediatr Radiol. 2025 Jun 9. doi: 10.1007/s00247-025-06260-z.
3
Caryophyllene Oxide, a Bicyclic Terpenoid Isolated from with Antitumor Activity: In Vivo, In Vitro, and In Silico Studies.
Int J Mol Sci. 2024 Dec 12;25(24):13355. doi: 10.3390/ijms252413355.
4
Inflammation-related markers and prognosis of alpha-fetoprotein producing gastric cancer.
World J Gastrointest Oncol. 2024 Sep 15;16(9):3875-3886. doi: 10.4251/wjgo.v16.i9.3875.
5
Characterization of Angiogenic, Matrix Remodeling, and Antimicrobial Factors in Preterm and Full-Term Human Umbilical Cords.
J Dev Biol. 2024 May 1;12(2):13. doi: 10.3390/jdb12020013.
6
Real world prognostic utility of platelet lymphocyte ratio and nutritional status in first-line immunotherapy response in stage IV non-small cell lung cancer.
Cancer Treat Res Commun. 2023;36:100752. doi: 10.1016/j.ctarc.2023.100752. Epub 2023 Aug 18.
7
Antiangiogenic Effect of Dopamine and Dopaminergic Agonists as an Adjuvant Therapeutic Option in the Treatment of Cancer, Endometriosis, and Osteoarthritis.
Int J Mol Sci. 2023 Jun 15;24(12):10199. doi: 10.3390/ijms241210199.
8
Systemic treatment for unresectable hepatocellular carcinoma.
World J Gastroenterol. 2023 Mar 14;29(10):1551-1568. doi: 10.3748/wjg.v29.i10.1551.
9
Vascular and Neuronal Network Formation Regulated by Growth Factors and Guidance Cues.
Life (Basel). 2023 Jan 19;13(2):283. doi: 10.3390/life13020283.
10
Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022.
Children (Basel). 2022 Dec 26;10(1):54. doi: 10.3390/children10010054.
本文引用的文献
1
mAbs: a business perspective.
MAbs. 2009 Mar-Apr;1(2):179-84. doi: 10.4161/mabs.1.2.7736. Epub 2009 Mar 21.
2
Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer.
PLoS One. 2009 Nov 3;4(11):e7669. doi: 10.1371/journal.pone.0007669.
3
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
J Clin Oncol. 2009 Oct 1;27(28):4733-40. doi: 10.1200/JCO.2008.19.8721. Epub 2009 Aug 31.
4
Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.
Nat Med. 2009 Sep;15(9):1023-30. doi: 10.1038/nm.2018. Epub 2009 Aug 9.
5
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules.
Nat Rev Clin Oncol. 2009 Sep;6(9):507-18. doi: 10.1038/nrclinonc.2009.110. Epub 2009 Jul 28.
6
Adverse effects of anticancer agents that target the VEGF pathway.
Nat Rev Clin Oncol. 2009 Aug;6(8):465-77. doi: 10.1038/nrclinonc.2009.94. Epub 2009 Jul 7.
7
Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Mol Cancer Ther. 2009 Jul;8(7):1761-71. doi: 10.1158/1535-7163.MCT-09-0280. Epub 2009 Jun 30.
8
Biomarkers of response and resistance to antiangiogenic therapy.
Nat Rev Clin Oncol. 2009 Jun;6(6):327-38. doi: 10.1038/nrclinonc.2009.63.
9
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
J Clin Oncol. 2008 Nov 20;26(33):5422-8. doi: 10.1200/JCO.2008.16.9847. Epub 2008 Oct 20.
10
The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
Curr Clin Pharmacol. 2008 May;3(2):132-43. doi: 10.2174/157488408784293705.
Zotero 插件